#1
|
|||
|
|||
Ðåçóëüòàòû äóïëåêñíîãî ñêàíèðîâàíèÿ è ïîêàçàíèÿ ê îïåðàòèâíîìó ëå÷åíèþ.
Öèòàòà:
Ýòà ÷àñòü òåìû ïåðåíåñåíà âî âðà÷åáíûé ðàçäåë, ïîñêîëüêó òðåáóåò îáùåãî îáñóæäåíèÿ, êîòîðîå íå èìååò îòíîøåíèÿ ê êîíêðåòíîé ïàöèåíòêå. |
#2
|
||||
|
||||
Òåìà äîñòàòî÷íî èíòåðåñíàÿ.  íàñòîÿùåå âðåìÿ ìíîãî ñîñóäèñòûõ õèðóðãîâ Ðîññèè ïðèñòóïèëè ê ðàçðàáîòêå ýòîé ïðîáëåìû, âûøëà ìîíîãðàôèÿ Ï.Î.Êàçàí÷ÿíà, çàùèùåíû äîêòîðñêèå äèññåðòàöèè È.Ñ.Àáðàìîâà, Ç.Ê.Ïèðöõàëàèøâèëè. Íî åñëè òåõíè÷åñêèå ïðîáëåìû ñîñóäèñòîé õèðóðãèè â ëå÷åíèè ïàòîëîãè÷åñêèõ èçâèòîñòåé â áîëüøåé ÷àñòè èìåþò ðåøåíèå, òî âîïðîñû àëãîðèòìà äèàãíîñòèêè, êëàññèôèêàöèè, ïîêàçàíèé ê îïåðàöèè îêîí÷àòåëüíî íå ðåøåíû.  äàííîé ïðîáëåìå òàêæå èãðàåò îãðîìíóþ ðîëü è îòñóòñòâèå êîîðäèíàöèè ìåæäó íåâðîëîãàìè è ñîñóäèñòûìè õèðóðãàìè. ( [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] ) Îòêðûòà äèñêóññèÿ íà òåìó ëå÷åíèÿ ïàòîëîãè÷åñêîé èçâèòîñòè ( [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] ).
Íî ìíîãîå óïèðàåòñÿ â àìáèöèè íåâðîëîãîâ è èõ íåæåëàíèå ïðèçíàâàòü çíà÷èìîñ÷òü ñîñóäèñòîé ïàòîëîãèè â ìåõàíèçìå ðàçâèòèÿ èøåìèè ìîçãà. ß íå ãîâîðþ î êîì-òî èíäèâèäóàëüíî, íî â ó÷åðåäèòåëüíûõ äîêóìåíòàõ ÍÀÁÈ (íàöèîíàëüíàÿ àññîöèàöèÿ ïî áîðüáå ñ èíñóëüòîì) ñòåíîç è îêêëþçèÿ ñîííûõ àðòåðèé è ñâÿçàííûé ñ íèì ïàòîôèçèîëîãè÷åñêèé ïðîöåññ íàðóøåíèÿ ìîçãîâîãî êðîâîîáðàùåíèÿ îáîçíà÷åí íå êàê ïðè÷èíà, à êàê ôàêòîð ðèñêà ðàçâèòèÿ èíñóëüòà è äðóãèõ ôîðì íàðóøåíèé ìîçãîâîãî êðîâîîáðàùåíèÿ (íîçîëîãè÷åñêîé åäèíèöû) íà 10-11 ìåñòå ìåæäó êóðåíèåì è çëîóïîòðåáëåíèåì àëêîãîëåì. Òàê åñëè ó ÍÀÁÈ òàêîå îòíîøåíèå ê ñîñóäèñòûì õèðóðãàì, ÷òî íàì æäàòü îò ðÿäîâûõ íåâðîëîãîâ? Çà 2005 ãîä â Ìîñêâå ñäåëàíî âñåãî 473 îïåðàöèè íà ìàãèñòðàëüíûõ àðòåðèÿõ ãîëîâíîãî ìîçãà (âêëþ÷àÿ ïîçâîíî÷íûå è ïîëäêëþ÷è÷íûå) ïðè ïîòðåáíîñòè 10-12 òûñ â ãîä. È óæ åñëè ñòåíîçû ñîííûõ àðòåðèé íå íàïðàâëÿþòñÿ íà õèðóðãèþ, ÷òî ãîâîðèòü î èçâèòîñòÿõ. À ðàñïðîñòðàíåííîñòü èçâèòîñòåé î÷åíü áîëüøàÿ: íåêîòîðûå àâòîðû äàþò äî 20-22% ñðåäè âñåé ïîïóëÿöèè. Ñèìïòîìíûõ çíà÷èòåëüíî ìåíüøå, íî è ïîñëåäñòâèÿ îò íèõ ãîðàçäî ñåðüåçíåå: ýòî ìîëîäûå ïàöèåíòû, ÷àñòî äåòè äî 15 ëåò ñ èñõîäíî ìèíèìàëüíîé êëèíèêîé è âíåçàïíûì çàâåðøåííûè èíñóëüòîì. Èòîã. åñòü ðàçðàáîòêè, åñòü ìàòåðèàë, åñòü îïûò, òðåáóåòñÿ ïîëíîöåííîå èññëåäîâàíèå |
#3
|
||||
|
||||
Öèòàòû ó÷àñòíèêîâ:
Öèòàòà:
Öèòàòà:
Öèòàòà:
Öèòàòà:
|
#4
|
|||
|
|||
What's New in Stroke? The Top 10 for 2004/05
Carotid Artery Stenosis It is generally accepted that carotid endarterectomy offers benefits for patients with high-grade (≥70%) cervical carotid stenosis who also have ipsilateral focal ischemic events (symptomatic stenosis), because the rate of stroke without surgery is high (~15% per year).[9] Symptomatic patients with mild stenosis (<50%) usually do not benefit from surgery;[10] for moderate stenosis (50–69%), modest benefit has been showed, and surgery is recommended for selected patients. Although carotid endarterectomy has been shown to reduce the risk of ipsilateral ischemic stroke for patients with asymptomatic carotid stenosis, the magnitude of this reduction is much smaller than for patients with symptomatic stenosis.[11] The Asymptomatic Carotid Surgery Trial (ACST) assigned 3,120 patients with asymptomatic cervical carotid artery stenosis of 60% or greater according ultrasound to best medical therapy versus best medical therapy plus endarterectomy.[12] During a mean follow-up of 3.4 years, endarterectomy reduced stroke (P < .001), with an absolute reduction of about 1% per year for those assigned to surgery. Although highly statistically significant, the number needed to treat was large; one stroke would be prevented for every 20 patients undergoing surgery and followed for 5 years. Paradoxically, although the ACST clearly demonstrated that surgery reduces stroke in patients with asymptomatic carotid stenosis, the absolute stroke risk in the medically treated arm was sufficiently low to question the routine use of endarterectomy in this setting. For those aged 75 and older, no benefit of surgery was evident. These results seem to reaffirm an initial conservative medical approach to most patients with asymptomatic carotid artery stenosis (and especially the very vigorous elderly) to include risk-factor management, antiplatelet prophylaxis, and periodic re-education about symptoms of TIA. J Am Geriatr Soc. 2006;54(4):674-679. ©2006 Blackwell Publishing |
#5
|
|||
|
|||
What's New in Stroke? The Top 10 for 2004/05
Carotid Angioplasty/Stenting Endovascular techniques for treating carotid stenosis have been developed over recent years. The advantages include avoiding general anesthesia in selected patients (because carotid surgery can be performed under local anesthesia), an incision in the neck, and the risk of cranial and cutaneous nerve damage from the surgical incision. Concern about distal embolization of debris during carotid artery angioplasty/stenting has led to the introduction and increasing use of cerebral protection devices,[13] although the endovascular procedure also carries risk of stroke and death, averaging about 6% in the initial 30 days. A recently published randomized trial that compared carotid surgery with angioplasty/stenting using a cerebral protection device, Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy, enrolled 334 patients with cervical carotid occlusive disease and included patients at high risk for carotid surgery.[14] All participants were given aspirin; in addition, those undergoing stenting received clopidogrel for the first 30 days. The main reasons for being considered "high risk" and hence eligible to participate were manifest coronary artery disease and age of 80 and older. The rate of periprocedural stroke was essentially equivalent, but early MI was lower in the stenting group than the endarterectomy group. In short, angioplasty/stenting resulted in lower risk of periprocedural MI than carotid endarterectomy in patients selected because of high cardiac risk for carotid endarterectomy. Although angioplasty/stenting is a reasonable option for such patients requiring carotid revascularization, the long-term durability of angioplasty/stenting, compared with that of endarterectomy, has not been established. Several large ongoing trials are addressing this issue. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] |
#6
|
||||
|
||||
Òàê êàêîé æå îòâåò?
Ñïàñèáî çà ñâîåâðåìåííûå ññûëêè. Íàñêîëüêî ÿ ïîíÿë ñìûñë îòêðûòèÿ òåìû, òàê ýòî óçíàòü ìíåíèå âðà÷åé-íåâðîëîãîâ î òîì êîãî è êîãäà îíè îòïðàâëÿþò ê ñîñóäèñòîìó õèðóðãó, à íå ÷èòàòü î ïîêàçàíèÿõ ê êàðîòèäíîé ÝÀÝ èëè àíãèîïëàñòèêå. Êñòàòè íå íåâðîëîãè è íå ñîñóäèñòûå õèðóðãè îïðåäåëÿþò íà çàïàäå ïîêàçàíèÿ ê îïåðàöèè. ( [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] ) Ïîêàçàíèÿ îïðåäåëÿþòñÿ ñîîòíîøåíèåì ôèíàíñîâûõ çàòðàò íà îäèí è òîò æå îáúåì ìåäèöèíñêîé ïîìîøè. Íàïðèìåð: ïîäñ÷èòàíî, ÷òî äëÿ òîãî ÷òîáû ïðåäîòâðàòèòü 1 èíñóëüò â ãðóïïå ñ àñèìïòîìíûìè ïàöèåíòàìè ñî ñòåíîçîì äî 50% íàäî ïðîîïåðèðîâàòü 26 òàêèõ áîëüíûõ. Òàê âîò íèêòî íå ãîâîðèò ÷òî îïåðàöèÿ áåñïîëåçíà, ãîâîðÿò ÷òî ìàòåðèàëüíûå çàòðàòû íà ëå÷åíèå 1 èíñóëüòà ìåíüøå ÷åì ïðîâåäåíèå 26 îïåðàöèé. È âñå! Ìû ìîæåì ñ Âàìè ñïîðèòü äî ïîñèíåíèÿ, íî ïîêàçàíèÿ íàì ñêàæóò òå, êòî çà ýòî ïëàòèò. È çàòåì, óæ åñëè ìû òàêèå ïðîãðåññèâíûå è ðàâíÿåìñÿ íà çàïàä â îïðåäåëåíèè ïîêàçàíèé ê õèðóðãèè, òîãäà äàâàéòå ðàâíÿòüñÿ è â ðàáîòå íåâðîëîãîâ. Íàïðèìåð, êàê äîëãî áóäåò ðàáîòàòü íåâðîëîã, íå íàïðàâëÿþùèé ìóæ÷èí ñòàðøå 55 ëåò íà äóïëåêñ? À ó íàñ ïðè ÒÈÀ - àñïèðèí è öèííàðèçèí ïî òàáëåòêå è âñå...
Òàê ÷òî äàâàéòå ãîâîðèòü î âàøåé ïîçèöèè è îòíîøåíèè ê ýòîìó âîïðîñó, à íå î òîì êàê ê íåìó îòíîñÿòñÿ íà çàïàäå. Ñ óâàæåíèåì ïðîô.Ëàâðåíòüåâ À.Â. |
#7
|
|||
|
|||
Óâàæàåìûé Àëåêñàíäð Âàäèìîâè÷!
Âåòêà áîëüøå äëÿ îáñóæäåíèÿ ïîêàçàíèé ê îïåðàòèâíîìó ëå÷åíèþ èçâèòîñòåé ñîñóäîâ. Åñëè ñ ëå÷åíèåì àòåðîñêëåðîòèå÷ñêèõ ñòåíîçîâ âñå áîëåå-ìåíåå ÿñíî, òî ñ èçâèòîñÿìè ÁÖÀ êàðòèíà ñîâñåì íå îäíîçíà÷íà. Âîïðîñ áûë - êàêèå èçâèòîñòè âñå òàêè íàäî îïåðèðîâàòü? Âñå èëè òîëüêî ãåìîäèíàìè÷åñêè çíà÷èìûå? Åñëè ïîñëåäíèå, òî êàêèìè êðèòåðèÿìè ãåìîäèíàìè÷åñêîé çíà÷èìîñòè ðóêîâîäñòâîâàòüñÿ? Íà ñâîåì ñàéòå Âû ïèøèòå, ÷òî äëÿ õèðóðãà êàæäàÿ æèçíü áîëüíîãî áåñöåííà. Íî è äëÿ íåâðîëîãà, îòïðàâëÿþùåãî íà îïåðàöèþ, ó êîòîðîé áûâàþò îñëîæíåíèÿ, æèçíü ïàöèåíòà íå áåçðàçëè÷íà. Ê òîìó æå îïèñûâàÿ óæàñû ñòðàõîâîé ìåäèöèíû Öèòàòà:
Âû çàáûëè ñêàçàòü, ÷òî âñå òàêè åñòü åùå ðèñê õèðóðãè÷åñêèé. Èìåííî îí îïðåäåëÿåò, èìååò ëè ñìûñë îïåðèðîâàòü àñèìïòîìíûé ñòåíîç. |
|
#8
|
||||
|
||||
Öèòàòà:
 Ðîññèè â ðÿäå êëèíèê ïðîâîäÿòñÿ îïåðàöèè ïðè èçâèòîñòÿõ ñîííûõ è ïîçâîíî÷íûõ àðòåðèé. Ïðè ýòîì îïðåäåëÿþùèì ôàêòîðîì ÿâëÿåòñÿ âûðàæåííîñòü êëèíèêè è ôîðìà èçâèòîñòè (ïîëíàÿ ïåòëÿ, îñòðûé óãîë). Îäíàêî Àáðàìîâ È.Ñ. â ñâîèõ ðàáîòàõ ïîêàçàë, ÷òî ôîðìà èçâèòîñòè ÿâëÿåòñÿ îòðàæåíèåì ñîáñòâåííî èçâèòîñòè íà ïëîñêîñòü è ïðè âðàùåíèè ýòîé 3D ìîäåëè ìîæåò ïëàâíî èçìåíÿòüñÿ îò Ñ- è S- èçâèòîñòè äî ñëîæíîé ïîëíîé ïåòëè. Óãîë èçâèòîñòè òàêæå ìåíÿåòñÿ â çàâèñèìîñòè îò ôàçû (ñèñòîëà, äèàñòîëà) è ñèñòåìíîãî äàâëåíèÿ. Òàêæå áûëî ïîêàçàíî, ÷òî íàèáîëåå èíôîðìàòèâíûì ïðèçíàêîì ÿâëÿåòñÿ ò.í. ñåïòà, êîòîðàÿ íå òîëüêî âûçûâàåò îãðàíè÷åíèå ïîòîêà êðîâè (êàê ñòåíîç) íî è ïðîäóöèðóåò ýìáîëû.  ñâîåé ïðàêòèêå ÿ ïðîâîæó îïåðàöèè ïðè ñëåäóþùèõ âàðèàíòàõ: 1. ñåïòàëüíûé ñòåíîç ïðè ïðàêòè÷åñêè ëþáîé êëèíè÷åñêîé ñèìïòîìàòèêå 2. çíà÷èòåëüíîå ñíèæåíèå öåðåáðàëüíîé ðåàêòèâíîñòè íà ñòîðîíå èçâèòîñòè Âîçìîæíî, ÷òî ñ òî÷êè çðåíèÿ äîêàçàòåëüíîé ìåäèöèíû ÿ è íå ïðàâ, íî çà 20 ëåò ðàáîòû ÿ ïðèíÿë äëÿ ñåáÿ èìåííî òàêóþ ïîçèöèþ. Ñëåäóåò òàêæå îòìåòèòü, ÷òî ïðè îïåðàöèÿõ ïî ïîâîäó èçâèòîñòè ïðàêòè÷åñêè íåò îñëîæíåíèé. À âîò íåîïåðèðîâàííàÿ ñåïòàëüíàÿ èçâèòîñòü êîí÷àåòñÿ òðîìáîçîì ñîííîé àðòåðèè. Ïî ïîâîäó ðèñêà îïåðàöèè, òàê ïðè ïðèìåíåíèè ñîâðåìåííûõ ïðåïàðàòîâ â êà÷åñòâå ïðåäîïåðàöèîííîé ïîäãîòîâêè è ñîâðåìåííûõ àíåñòåòèêîì ðèñê îïåðàöèè íå âûøå 1.0-1.5%. |
#9
|
||||
|
||||
ñõåìà
À âîò è ñõåìà ïëàâíîãî èçìåíåíèÿ òèïà èçâèòîñòè â çàâèñèìîñòè îò óãëà ïîâîðîòà ìîäåëè èçâèòîñòè. Òóò åñòü è Ñ-òèï, è S-òèï è ïîëíàÿ ïåòëÿ. Åñòü è îñòðûé óãîë, ïåðåõîäÿùèé â òóïîé è ò.ä.
|
#10
|
||||
|
||||
Öèòàòà:
|
#11
|
||||
|
||||
Óâàæàåìûé Stroke!
Âû ñ÷èòàåòå, ÷òî åñëè ìû (íåâðîëîãè) íå ïîñûëàåì ïàöèåíòîâ ê Âàì, òî ýòî çíà÷èò - íèêóäà íå ïîñûëàåì? Ìîãó îòâåòèòü çà ÃÊÁ ¹11 (íàäåþñü, êîëëåãè ïîääåðæàò): ïî ïîêàçàíèÿì, ñ êàðòèíêàìè äîïïëåðà, àêòèâíî íàïðàâëÿåì áîëüíûõ ê ñîñóäèñòûì õèðóðãàì. Ïðîñòî ñëîæèëèñü âçàèìîîòíîøåíèÿ ñ îïðåäåëåííûìè êëèíèêàìè, ïîäõîäû è ðåçóëüòàòû êîòîðûõ íàñ óñòðàèâàþò. À äèñêóòèðîâàòü îñîáåííî è íå î ÷åì. |
#12
|
||||
|
||||
Öèòàòà:
|
#13
|
||||
|
||||
Óâàæàåìûé ïðîôåññîð Èíñóëüò! Äåëî íå â íåâðîëîãàõ, à â ïàöèåíòàõ. Åñëè ìû âûÿâèëè ïðîöåññ, ïðèâîäÿùèé ê ñíèæåíèþ ÎÑÊ ïî îäíîìó èç ÌÀÃ è ïðè ýòîì íåò âûðàæåííîé êëèíèêè, áîëüíîé ïîä íîæ íå ïîéäåò. À êîãäà "æàðåíûé ïåòóõ êëþíåò" â âèäå ãåìèïëåãèè, òî, ñàìè ïîíèìàåòå, óæå ñìûñëà íå áóäåò. Â ýòîì îòíîøåíèè êîðîíàðíûå áîëüíûå áîëåå àäåêâàòíû.
|
#14
|
|||
|
|||
Öèòàòà:
Âû ïðåäëàãàåòå îïåðèðîâàòü ïðè Öèòàòà:
Íóæíû êîêðåòíûå öèôðû, òîãäà è ìîæíî îáñóæäàòü. Âû ïèøåòå: Öèòàòà:
Âèäåë ÿ îäíîãî ìàëü÷èêà 23õ ëåò, ñ ãîëîâíûìè áîëÿìè, êîòîðîãî ñîñóäèñòûå õèðóðãè ïîëå÷èëè îò èçâèòîñòè ÏÀ. Ðåçóëüòàò ëå÷åíèÿ -àôàçèÿ ñ ãåìèïàðåçîì. Êîíå÷íî, òåïåðü îí íà ãîëîâíûå áîëè íå æàëóåòñÿ . |
#15
|
||||
|
||||
Öèòàòà:
Öèòàòà:
Òåïåðü ïî äåëó. Àíàëîãèÿ ñ êîðîíàðíûìè áîëüíûìè ïðåêðàñíà è îíà ïîíÿòíà íå òîëëüêî âðà÷àì, íî è ïàöèåíòàì. È íàäî èì äîíîñèòü ÷òî ìîçã íå ìûøöà (ñåðäöå èëè èêðà) è íå èìååò íåðâíûõ îêîí÷àíèé, ÷òî ðèñê îïåðàöèè íå ñîïîñòàâèì ñ ðèñêîì ðàçâèòèÿ èíñóëüòà êàê ïðè åñòåñòâåííîì òå÷åíèè áîëåçíè, òàê è ïðè ïðîâîäèìîì ëå÷åíèè., ÷òî 70% èíñóëüòîâ âîçíèêàþò áåç ïðåäâàðèòåëüíîé ìàëîé ñèìïòîìàòèêè è ò.ä. È òîãäà, åñëè Âû ïîñòàâèëè äèàãíîç, òî áîëüíîé Âàì âåðèò è îí áóäåò ïðèñëóøèâàòüñÿ ê Âàøåìó àâòîðèòåòíîìó ìíåíèþ è ïîéäåò ê òåì õèðóðãàì, êîòîðûõ Âû ïîðåêîìåíäóåòå èì. È ïîñëå îïåðàöèè áîëüíîé ïðèäåò ê Âàì äëÿ äîëå÷èâàíèÿ, ðåàáèëèòàöèè (åñëè îíà íóæíà) èëè ïðîñòî ñî ñëîâàìè áëàãîäàðíîñòè. Òåïåðü î ìåòîäîëîãèè. ÎÑÊ - îáúåìíàÿ ñêîðîñòü êðîâîòîêà - äàâíî íå ÿâëÿåòñÿ ïîêàçàòåëåì àäåêâàòíîãî/íåàäåêâàòíîãî êðîâîòîêà. È îðèåíòèðîâàòüñÿ ïî ýòîìó ïîêàçàòåëþ ïðîñòî âðåäíî. Ñêàæó áîëüøåå, ÷òî è ëèíåéíûå ñêîðîñòè êðîâîòîêà ïî äàííûì ÓÇÄÑ òàêæå íå ÿâëÿþòñÿ èñòèííûìè. Ýòî àïïàðàòíûå ñêîðîñòè, õàðàêòåðíûå äëÿ êàæäîãî òèïà ïðèáîðà, à ïîòîìó è ÎÑÊ íå áóäåò èìåòü íè÷åãî îáùåãî ñ èñòèííîé êàðòèíîé ìîçãîâîãî êðîâîîáðàùåíèÿ. ß çíàþ äîëêòîðñêóþ äèññåðòàöèþ â êîòîðîé ðàñ÷åòíàÿ ÎÑÊ ïî ÂÑÀ áûëà 37-40 ñì/êóá/ñåê ÷òî ñîñòàâëÿåò ïðèáëèçèòåëüíî 2.3 ëèòðà â ìèíóòó. Åñëè Âàì èíòåðåñíî ÿ îòäåëüíî ïîñòàðàþñü îáúÿñíèòü ãäå êðîåòñÿ îøèáêà. Öèòàòà:
Íà âîïðîñû åñòåñòâåííîãî òå÷åíèÿ èçâèòîñòè ÿ íå ìîãó îòâåòèòü, Âû òðåäóåìå îò ìåíÿ ðåçóëüòàòîâ ðàáîòû äàæå íå îäíîãî íàó÷íîãî öåíòðà. Îöåíêà ýôôåêòèâíîñòü îïåðàöèè íàìè ïðîâîäèëàñü ïî äèíàìèêå ðåçåðâà. Ïðè âûñîêîé ðåàêòèâíîñòè îíà ïîñëå îïåðàöèè íå ìåíÿåòñÿ, à âîò ïðè íèçêîé ïðîèñõîäèò ðåçêèé ïîäúåì äî ïðàêòè÷åñêè íîðìàëüíûõ âåëè÷èí. Èìåííî ïî ýòîìó ïîêàçàòåëþ ìû è îïðåäåëèëè ïîãðàíè÷íûå öèôðû ðåàêòèâíîñòè äëÿ ïîêàçàíèé ê îïåðàöèè. Âîçìîæíî ìåòîäîëîãè÷åñêè ýòî íå âåðíî, äåéñòâèòåëüíî íàäî ïðîñëåäèòü åñòåñòâåííûé õîä èçâèòîñòè ÂÑÀ, íî , ïîâåðüòå, òðóäíî îòñëåäèòü îïåðèðîâàííûõ ïàöèåíòîâ, à ñëåäèòü çà ïàöèåíòàìè êîòîðûå îòêàçàëèñü îò ëå÷åíèÿ â êëèíèêå - ýòî óæå ñëèøêîì. Äàâàéòå ñäåëàåì òàêóþ ðàáîòó! ß íå ðàñ÷èòûâàþ íà ñâîþ ïåðñîíó, ìåíÿ âïîëíå áû óñïðîèëà ïðîñòî îáúåêòèâíàÿ èíôîðìàöèÿ êîòîðîé ïîêà íåò íè ó êîãî. Äàëåå î ðåçóëüòàòàõ - ó Âàñ êî ìíå ïðåäâçÿòîå îòíîøåíèå è î ñåáå íå èáóäó. Íà ìíîãèõ ñúåçäàõ ïîäðÿä ïðàêòè÷åñêè âñå ñîñóäèñòûå õèðóðãè îòìå÷àþò íàìíîðãî áîëåå äîáðîæåëàòåëüíîå òå÷åíèå ï\î ïåðèîäà ó áîëüíûõ è íóëåâóþ ëåòàëüíîñòü ñ 0.3-0.5% 30-äíåâíûì êîë-âîì îñëîæíåíèé. ÄÎÏÎËÍÅÍÈÅ: ñïàñèáî çà "ÍÅÎÄÎÁÐßÌÑÛ". Èç Âàøèõ óñò ýòî êàê ïðåìèÿ ê çàðïëàòå. Ãëàâíîå ÷òî âñå-òàêè ÿ Âàñ ðàñøåâåëèë. |